ASSESS: Double-blind, placebo-controlled, Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome

Protocol Name: ASSESS: Double-blind, placebo-controlled, Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome Protocol #: 22419 Indication: Alport Syndrome GFR: ≥45 Principal Investigator: Ankit Mehta, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS […]

ASSESS: Double-blind, placebo-controlled, Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome Read More »